Background: antipsychotic drugs (APs) have been associated with falls and fractures in elderly individuals but limited knowledge on specific drugs exist. Objective: to investigate the association between individual APs and fractures in elderly persons. Design and setting: nationwide register-based cohort study. Subjects: all Danish individuals aged ≥65 who had not been in treatment with any AP in the year before inclusion. Methods: incidence rate ratios (IRRs) of fractures of hip, pelvis or upper extremities during treatment with commonly used APs were assessed in multivariable Poisson models. Exposure was divided into time periods from initiation of treatment: 0-30 days, 31-365 days or >365 days. Results: one year prior to inclusion, 1,540,915 individuals ≥65 years had not received APs and of these 93,298 initiated treatment with APs. Mean follow-up was 9.6 years. During follow-up, 246,057 (16%) experienced a fracture. Associations were for all APs highest in the initial treatment period (0-30 days) with IRRs for risperidone 1.97 (95% CI: 1.70-2.28), olanzapine 2.31 (95% CI: 1.96-2.73), quetiapine 2.09 (95% CI: 1.73-2.52), zuclopenthixol 2.19 (95% CI: 1.82-2.63), chlorprothixen 1.62 (95% CI: 1.18-2.24), flupenthixol 1.43 (95% CI: 1.06-1.93), levomepromazine 1.19 (95% CI 0.86-1.66), haloperidol 2.98 (95% CI 2.57-3.45), compared with the background population. Conclusions: use of APs is associated with fractures in elderly persons especially in the initial treatment period. If AP use in an elderly person is deemed necessary, individual falls prophylaxis should be considered.
Introduction
Treatment with APs have been associated with adverse events the most serious being cerebrovascular events and death. In 2005, The US Food and Drug Administration (FDA) concluded that the use of second-generation antipsychotic (SGA) drugs in elderly patients with dementia was associated with increased mortality, as estimated from a metaanalysis of 17 randomised placebo controlled trials and issued a warning against use in persons with dementia. Later, several studies demonstrated that the risk of serious adverse events associated with first-generation antipsychotic (FGA) drugs was comparable or even higher, and in 2008, the FDA extended the warning to include FGAs as well [1] . Whereas some of the increased mortality may be explained by cardiovascular adverse events, the causes of increased mortality are indeed incompletely understood.
Falls and fragility fractures have been associated with the use of APs in elderly persons [2] [3] [4] [5] [6] [7] . Somnolence, extrapyramidal side effects and gait abnormalities are all well recognised side effects of APs and may contribute to the risk of falls in elderly persons [8] . Observational and experimental studies have shown that APs increase postural sway especially in elderly person [9, 10] . APs may therefore increase risk of falls and fall-related fractures, which are associated with very high mortality in elderly individuals.
Fragility fractures are fractures that result from mechanical forces that would not ordinarily result in fracture, known as lowlevel (or 'low energy') trauma. The World Health Organization (WHO) has quantified this as forces equivalent to a fall from a standing height or less [11] . Fragility fractures are a major health problem for elderly people. Approximately 80% of all fragility fractures in elderly individuals are due to falls [12] . Among community-dwelling elderly populations 30-60% fall at least once every year, and serious injuries occur in 5-10% of all falls [13] .
However, existing knowledge on the association between use of APs and falls/fractures is insufficient. Furthermore, there are only few head-to-head trials that might inform the choice between specific APs, when this treatment is deemed necessary. Due to the warnings against use of antipsychotics in elderly persons with dementia, it probably would be ethical inappropriate to perform further randomised clinical trials investigating the association between APs and falls/ fractures. However, APs are still widely used in this patient group. With the present large population-based study, we therefore aimed to investigate the occurrence of fractures associated with use of APs and to assess the strength of a possible association with the use of specific APs.
We have previously used Danish registers to study associations between the use of cardiovascular drugs and fragility fractures. In this study, we have applied a similar method in order to explore the association between fragility fractures and APs [14] .
Material and methods

Population and databases
This study is a nationwide register-based Danish cohort study. We included all residents in Denmark aged 65 or older between 1 January 1999 and 31 December 2012 who had no treatment with APs 1 year prior to inclusion. The Danish data protection agency approved the study (j.nr:2007-58-0015/local j.nr. GEH-2014-013 I-Suite no. 02731). In Denmark, no ethics approval is required for register-based studies in which persons cannot be identified. For administrative purposes, all Danish citizens since 1968 have a unique personal identification number. This identification number enables individuallevel linkage of Danish citizens through several national registries. Information about all births and deaths are registered in the Danish Civil Registration System and has been complete since 1968 [15] . The Danish National Patient Registry contains records of all hospitalisations since 1977 [16] . Finally, the Danish Registry of Medicinal Products Statistics contains data on all prescription claims in Denmark since 1995, including information about medicine strength, quantity dispensed and dispensing date [17] . Prescriptions are classified according to the Anatomical Therapeutic Chemical (ATC) system.
Fractures
Fractures, were identified in the Danish National Patient Registry if an individual was hospitalised with one of the following diagnoses classified with the International Classification of Diseases 10th revision (ICD-10): fracture of sacrum (S321), fracture of coccyx (S322), fracture of ilium (S323), fracture of acetabulum (S324), fracture of pubis (S325), fracture of shoulder and arm (S42), fracture of forearm (S52), fracture at wrist and hand level (S62) and fracture of femur (S72). In addition, we identified whether the fracture occurred during hospitalisation and whether an individual had experienced previous fractures.
Pharmacotherapy and duration of treatment
From the Danish Registry of Medicinal Products Statistics, we identified exposure to the following first-generation APs (ATC codes in brackets): zuclopenthixol (N05AF05), chlorprothixene (N05AF03), flupentixol (N05AF01), levomepromazine (N05AA02), haloperidol (N05AD01); and the following second-generation APs: risperidone (N05AX008), olanzapine (N05AH03), quetiapine (N05AH04).
We also identified exposure to the following commonly used cardiovascular drugs and benzodiazepines suspected to be associated with fragility fractures (ACT codes in brackets): nitrates (C01DA08, C01DA14), digoxin (C01AA05), thiazide (C03AB01), ACE inhibitors (C09AA01, C09AA02, C09AA03, C09AA04, C09AA05, C09AA10), furosemide (C03CA01), calcium antagonists (C08CA01, C08CA02, C08DA01, C08DB01), beta-blockers (C07AA05, C07AB02, C07AB03, C07AB07, C07AG02), statins (C10AA01, C10AA03, C10AA05, C10AA07), angiotensin receptor antagonists (C09CA01, C09CA03, C09CA04, C09CA06, C09CA07, C09CA08), benzodiazepines (N05CD02, N05CD05, N05CD06, N05CF01, N05 CF02, N05BA01, N05BA04, N05BA12).
For all agents, exposure status was determined by using prescription claims from the Danish pharmacies as registered in the Danish Registry of Medicinal Products Statistics. The registry contains information on tablet strength and number of tablets but not on dosage. For each specific drug, we defined minimum, maximum and typical daily dosages for each drug. When a patient first started treatment, the typical dosage was used to calculate duration of treatment. During the study, patients might have their dosage changed, and we therefore used up to five previous consecutive prescriptions to calculate the daily dosage. If calculated dosage exceeded the predefined maximum dose, tablets were assumed to be stored and the maximum dosage was used for calculation of treatment period. Stored tablets were assumed to be consumed during the period following the last prescription.
Comorbidities
We identified comorbidities known to be associated with falls from in-hospital diagnoses from the Danish National Patient Registry: myocardial infarction, stroke, hypertension, heart failure, chronic obstructive pulmonary disease (COPD), cancer, diabetes, depression, dementia, osteoporosis, Parkinson's disease, and acute delirium [18] . All comorbidities were identified from 1977 and throughout the observation period. Participants were classified as having the disease from the first day of diagnosis. Some diseases are primarily diagnosed in an outpatient setting and we therefore included relevant medications from the Danish Registry of Medicinal Products Statistics to identify these comorbidities. We did that for the following diseases (ATC codes in brackets): depression (N06A), dementia (N06D), diabetes (A10), osteoporosis (M05B) and Parkinson's disease (N04).
Statistics
We applied time-dependent multivariable Poisson regression models to test the association between the different APs and fractures. Prior to analysis observational time was divided into bands of 1-year intervals and age was updated at the start of each time-band. To ensure timely correct categorisation of comorbidities and exposure, all comorbidities and treatment status were included as time-dependent variables. The importance of time since initiation of the different APs was explored by including variables as use versus no use of a specific agent in a specific time window (e.g. 'risperidone 0-30 days', 'haloperidol 31-365 days', etc.). The Poisson regression model was adjusted for age, sex, calendar year, comorbidities, whether the fragility fracture occurred in-hospital and concurrent pharmacotherapy with cardiovascular drugs, benzodiazepines and other APs. Furthermore, we performed a sensitivity analysis where we excluded individuals with a cancer diagnosis in order to address possible confounding by indication. In other sensitivity analyses, we stratified on dementia and on depression. All analyses were conducted using SAS, version 9.4 (SAS Institute, Cary, NC, USA), a two-sided P-value of <0.05 was considered statistically significant.
Results
We identified 1,540,915 individuals who had not been in treatment with APs in the year prior to inclusion, of these 93,298 initiated treatment with APs. On average, individuals were followed for 9.6 years (max = 14 years), and loss to follow-up due to emigration was minimal (0.3%).
During follow-up, 246,057 individuals (16%) experienced a fragility fracture; of these 10,265 (0.7%) were pelvis fractures, 46,684 (3%) fractures of shoulder and upper arm, 72,912 (4.7%) fractures of the forearm, 26,586 (1.7%) fractures of wrist or hand and 89,620 (5.8%) were femoral fractures. Of all fractures, 2.9% occurred during treatment with APs. Population characteristics for individuals exposed to the different APs during follow-up and unexposed individuals are shown in Table 1 . Overall, individuals treated with APs had more comorbidity than unexposed.
Total exposure time, and numbers of fractures associated with use of each drug and for unexposed individuals are given in Table 2 . As seen in the table, we observed increased crude incidence rates for all APs compared to unexposed. Highly increased incidence rates were observed among patients treated with haloperidol, olanzapine, zuclopenthixol, risperidone and quetiapine.
In the multivariable Poisson regression analysis, all APs but levomepromazine were associated with increased incidence rate ratio (IRR) of fractures compared to unexposed. Overall adjusted IRR for fracture associated with APs was 2.23 during the first 30 days of treatment. For all APs, the observed associations were highest shortly after treatment initiation and gradually declined over time, as shown in Figure 1 . For haloperidol and zuclopenthixol, the IRR remained highly increased 1 year after first exposure. Exclusion of cancer patients showed no significant change in risk estimates. Stratification on dementia and on depression showed that patterns of association were the same for patients with and without dementia, and with and without depression, please see the table in appendix 1 in the supplementary data on the journal website http://ageing. oxfordjournals.org/.
Discussion
In this study, including all Danes above the age of 65 and with no use of APs 1 year prior to inclusion, we investigated the association between different APs and risk of fractures. We included fracture diagnoses with a high probability of being fragility fractures. We found that all APs with the exception of levomepromazine were significantly associated with fractures. For all drugs, the association was strongest shortly after treatment initiation and thereafter declined. We did not find any significant differences between IRRs of SGAs included (risperidone, olanzapine and quetiapine). In the group of FGAs, IRRs of zuclopenthixol, chlorprothixen and flupenthixol were similar. The association between fractures and haloperidol with an IRR of 3.06 (CI 2.64-3.55) was significantly stronger than with any other AP.
Safety of AP use in elderly persons
In elderly persons, antipsychotics are often used for offlabel indications. Falls are a major cause of morbidity and mortality in dementia with an increase of up to eight times the risk compared to persons with no dementia [19] .
Hip fractures are associated with a high mortality. The most common causes of death after hip fracture are respiratory infections, ischaemic heart disease and cardiac failure [20] . Thus, it is possible that fractures especially hip fractures mediate some of the excess mortality known to be associated with use of APs [21] [22] [23] .
Use of APs and falls in elderly individuals
The outcome in this study was fragility fractures. However, 80% of all fragility fractures in elderly individuals are due to falls, and fragility fractures may therefore be seen as a proxy for falls [12] . Prior studies have shown conflicting results Population characteristics for users and non-users of AP's. Numbers are presented as counts for discrete variables and means (SD) for continuous variables. Characteristics of the treatment-groups refer to those obtained at first day of treatment; thus, groups are not exclusive. For the 'no treatment' group, characteristics were obtained at day of inclusion in the study. Abbreviations: AMI, acute myocardial infarction; COPD, chronic obstructive pulmonary disease; Ca-antagonists, calcium antagonists; ARB, angiotensin receptor blockers.
concerning the association between use of APs and the occurrence of falls in elderly persons. However, side effects in the form of extrapyramidal movement disorders, gait disturbance, postural instability and orthostatic hypotension are well recognised and it is likely that these side effects may lead to falls. One controlled randomised trial showed that patients with dementia and especially those with the symptom of wandering had less falls when treated with risperidone in low dose (1 mg/d) but patients without wandering had a higher risk of falls when treated with 2 mg/d [24] . This finding demonstrates how complex the evaluation of the association between APs and falls may be.
Several 
(CI: 0.94-2.00) [25] .
Schneider et al. found no significant association between APs and falls in patients with dementia. However, only 8 of the 15 included trials reported data on falls [26] .
Tan et al. found no association between use of SGAs and injuries or falls. The majority of the studies included were industry driven efficacy studies not designed or powered to estimate falls risk. Several of the included studies did not report data on falls [27] .
In a recent metaanalysis on drugs with anticholinergic effects, olanzapine was associated with falls (OR 2.16, CI: 1.05-4.44), but risperidone was not (RR 1.39, CI: 0.59, 3.26) [28] .
A major limitation in studies concerning falls is the method of falls and medication ascertainment. Especially recalling and reporting falls may be difficult for patients with cognitive problems like dementia or delirium. In our study, we have eliminated recall bias by using fragility fractures rather than falls as outcome.
Use of APs and fractures
Fragility fractures are due to a combination of falls and osteoporosis and thus the risk of fracture is dependent on the risk of falls and on bone mass density.
However, in our study, the fact that the association between APs and fractures was strongest immediately after initiation of AP treatment indicates that fractures associated with APs in an elderly population may be due to increased risk of falls rather than bone mineral density loss.
The findings in our study are comparable to another recent large population-based study; using a matched cohort design Fraser et al. found a significant association between use of SGAs and fragility fractures with an OR of 1.51 (CI: 1.41-1.60) and a similar association with falls [29] .
In a recent metaanalysis, Oderda et al. found a significant association between hip fractures and use of psychotropic drugs in elderly individuals with ORs for FGAs 1.68 (CI: 1.43-1.99) and for SGAs 1.30 (CI: 1.14-1.49) [30] .
Time between treatment initiation and fractures
In general, a temporal relationship between initiation of a drug and occurrence of an adverse event is assumed to be an important criteria for classifying an event as an adverse event [31] . APs are known to be associated with gait disturbances, anticholinergic effects that may influence cognition, and cardiovascular symptoms (i.e. hypotension, ischaemic events and arrhythmias). We would assume these symptoms to occur in patients at risk immediately or shortly after initiation of treatment. The table shows numbers of fragility fractures, and crude incidence rates during non-exposure and during exposure to different antipsychotic agents.
Strengths and limitations
The main strength is the large population enabling us to investigate the associations between fragility fractures and treatment with individual drugs. Furthermore, in Denmark, medical care is offered to all citizens without copayment and medications are reimbursed by the state. Thus, we consider possible bias due to socioeconomic differences to be minimal. The Danish registers contain valid information on comorbidities and drug-use and we were therefore able to adjust for important comorbidities and use of other drugs. An observational population study makes it possible to study real-world data. The randomised controlled trials typically have studied treatment with APs in patients with welldefined Alzheimer's disease. In the real world, APs are prescribed off-label to patients with neuropsychiatric symptoms possibly due to very different underlying diseases like acute delirium and other types of dementia. However, the observational design means that we cannot make any conclusions on causality. Thus, we cannot fully exclude bias due to lacking information on important clinical variables like acute delirium that in itself might lead to falls and fragility fractures, state of dementia, type of neuropsychiatric symptoms and other details on reasons for off-label use of antipsychotics. The fact that the patterns of association did not differ in sensitivity analyses stratified by dementia or depression suggests that our findings may not be explained by indication bias or by other medical treatment.
We have used fracture diagnoses in order to estimate the association between falls and APs. Some fractures may not have been caused by falls. However, approximately 80% of fragility fractures in elderly persons are due to falls [12] .
Conclusion
In summary, the findings in this study strengthen the existing evidence of association between the use of APs and occurrence of falls and fractures in elderly persons. Due to the large population, we were able to study specific drugs. The association with fractures is not significantly different among FGAs. Haloperidol showed a significant stronger association compared to all other APs. We did not find any systematic differences between FGAs and SGAs. Our findings support the conclusion that the role of APs in the treatment of elderly patients with neuropsychiatric symptoms should be limited due to serious adverse events. When AP use in an elderly individual is deemed necessary, focus on individual falls prophylaxis should be considered.
Key points
• APs are associated with fractures in elderly persons.
• First-generation and second-generation antipsychotics are equally associated with fractures.
• Especially when starting treatment with antipsychotics the risk of falls and fractures should be considered.
Supplementary data
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